Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | NOS1 | P29475 | 3/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.53 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.53 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.53 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.53 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575003 | 0.98 | MEN1 (0.58) | MEN1KMT2ANOS1GRIN2DGRIN3B | |
| SCHEMBL9290906 | 0.96 | MEN1 (0.61) | MEN1KMT2ANOS1GRIN2DGRIN3B | |
| SCHEMBL9415798 | 0.96 | MEN1 (0.61) | MEN1KMT2ANOS1GRIN2DGRIN3B | |
| SCHEMBL9290797 | 0.91 | — | — | |
| Maleic Acid SCHEMBL5151421 | 0.84 | MEN1 (0.44) | MEN1KMT2ANOS1GRIN2DGRIN3B | |
| SCHEMBL9290971 | 0.81 | — | — | |
| SCHEMBL20779515 | 0.80 | LMNA (0.55) | MEN1KMT2ANOS1GRIN2DGRIN3B | |
| SCHEMBL9059398 | 0.80 | MEN1 (0.58) | MEN1KMT2ANOS1GRIN2DGRIN3B | |
| SCHEMBL7041301 | 0.77 | MEN1 (0.59) | MEN1KMT2AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL6159793 | 0.77 | GRIN2D (0.62) | MEN1KMT2AGRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008095903-A1 | NEW ADDITION SALT OF N-AMINO-N'-PENTYLGUANIDINE, THE PROCESS FOR ITS PREPARATION AND USE THEREOF FOR OBTAINING TEGASEROD | CHEMO IBÉRICA, S.A. (ES) | 2008-08-14 | — | — | WO | claimed |
| EP-1955998-A1 | New addition salt of N-amino-N'-pentylguanidine, the process for its preparation and use thereof for obtaining tegaserod | Chemo Ibérica, S.A. (ES) | 2008-08-13 | — | — | EP | claimed |
| WO-2007119109-A2 | PROCESSES FOR PREPARING TEGASEROD MALEATE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | MEDICHEM, S.A. (US) | 2007-10-25 | — | — | WO | claimed |
| WO-2007120924-A1 | PREPARATION OF TEGASEROD MALEATE FREE OF IODIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-10-25 | — | — | WO | claimed |
| US-20070225507-A1 | Process for preparing a crystalline form of Tegaserod maleate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-09-27 | — | — | US | claimed |
| US-20070208072-A1 | Maleate salt of tegaserod and crystalline forms thereof | TEVA PHARMACEUTICALS USA, INC. | 2007-09-06 | — | — | US | claimed |
| WO-2007084761-A1 | MALEATE SALT OF TEGASEROD AND CRYSTALLINE FORMS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-26 | — | — | WO | claimed |
| WO-2007084697-A2 | PROCESS FOR PREPARING A CRYSTALLINE FORM OF TEGASEROD MALEATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-26 | — | — | WO | claimed |
| EP-1740539-A2 | PREPARATION OF TEGASEROD AND TEGASEROD MALEATE | Teva Pharmaceutical Industries Ltd (IL) | 2007-01-10 | — | — | EP | claimed |
| US-20060106086-A1 | Preparation of tegaserod and tegaserod maleate | TEVA PHARMACEUTICALS USA, INC. | 2006-05-18 | — | — | US | claimed |
| WO-2005105740-A2 | PREPARATION OF TEGASEROD AND TEGASEROD MALEATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-11-10 | — | — | WO | claimed |
| WO-2008095903-A1 | NEW ADDITION SALT OF N-AMINO-N'-PENTYLGUANIDINE, THE PROCESS FOR ITS PREPARATION AND USE THEREOF FOR OBTAINING TEGASEROD | CHEMO IBÉRICA, S.A. (ES) | 2008-08-14 | — | — | WO | disclosed |
| EP-1955998-A1 | New addition salt of N-amino-N'-pentylguanidine, the process for its preparation and use thereof for obtaining tegaserod | Chemo Ibérica, S.A. (ES) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007126889-A1 | PREPARATION OF TEGASEROD ACETATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007120924-A1 | PREPARATION OF TEGASEROD MALEATE FREE OF IODIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-10-25 | — | — | WO | disclosed |
| EP-1723106-A2 | PURIFICATION OF TEGASEROD MALEATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-11-22 | — | — | EP | disclosed |
| US-20060128788-A1 | Purification of tegaserod maleate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-06-15 | — | — | US | disclosed |
| US-20060106086-A1 | Preparation of tegaserod and tegaserod maleate | TEVA PHARMACEUTICALS USA, INC. | 2006-05-18 | — | — | US | disclosed |
| WO-2006045120-A2 | PURIFICATION OF TEGASEROD MALEATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-04-27 | — | — | WO | disclosed |
| WO-2005105740-A2 | PREPARATION OF TEGASEROD AND TEGASEROD MALEATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208072-A1 | Maleate salt of tegaserod and crystalline forms thereof | SLC10A2, TTR, MYO3A | MEN1 139/4885KMT2A 3065/4885NOS1 2179/4885 |
| US-20060128788-A1 | Purification of tegaserod maleate | MLNR, FABP6, SI | MEN1 1774/4885KMT2A 1823/4885NOS1 3401/4885 |
| US-20060106086-A1 | Preparation of tegaserod and tegaserod maleate | MLNR, SLC10A2, MLN | MEN1 371/4885KMT2A 1159/4885NOS1 3383/4885 |
| US-20070225507-A1 | Process for preparing a crystalline form of Tegaserod maleate | MLNR, SI, MLN | MEN1 1399/4885KMT2A 2958/4885NOS1 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.